Tren Terapi Age-Related Macular Degeneration

Authors

  • Alicia Pricelda Jakarta, Indonesia

DOI:

https://doi.org/10.55175/cdk.v48i12.176

Keywords:

Age-related macular degeneration, AMD, kebutaan, penyakit retina

Abstract

Dahulu penyakit retina memiliki prioritas rendah dalam strategi pencegahan kebutaan di negara berkembang karena masih jarang dikenal sebagai penyebab kebutaan, peralatan belum cukup canggih, dan kurangnya tenaga medis sub-spesialistik penyakit retina. Seiring kemajuan ilmu pengetahuan dan teknologi, penyakit retina saat ini diketahui merupakan salah satu penyebab kebutaan utama terutama pada anak. Masih belum banyak pilihan terapi penyakit retina, tetapi pasien berhak mendapatkan diagnosis yang akurat, penjelasan yang baik, dan prognosis yang jelas. Artikel ini membahas salah satu penyakit retina, yaitu age-related macular degeneration (AMD), pengobatan yang tersedia dan yang sedang dikembangkan.

Previously, retinal diseases had low priority in preventing blindness strategies in developing countries because they are rarely known as the cause of blindness, no available sophisticated diagnostic equipment, and also lack of medical personnel with sub-specialties in retinal diseases. With the advancement of science and technology, retinal disease is now currently known as one of the main causes of blindness, especially in children. Limited therapies are currently available, but patients still deserve an accurate diagnosis, good explanation, and a clear prognosis. This article discusses one of the retinal diseases : age-related macular degeneration (AMD), its existing and emerging treatments.

Downloads

Download data is not yet available.

References

David Y. Retinal disease and vision 2020. J Community Eye Health. 2003;16(46):19-20.

Camelo S, Latil M, Veillet S, Dilda PJ, Lafont R. Beyond AREDS formulaitons, what is next for intermediate age related macular degeneration (iAMD) treatment? Potential benefits of antioxidant and anti-inflammatory apocarotenoids as neuroprotectors. Oxid Med Cell Longev. 2020;2020:4984927. doi:10.1155/2020/4984927.

Rupert R. Cause of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidables blindness in relation to vision 2020: The right to sight: An analysis for the global burden of disease study. Lancet Glob Health. 2021;9:144-60. doi:10.1016/S2214-109X(20)30489-7.

Fatima T, Asim K, Anika T, Hasan M. A mechanistic review of b carotene, lutein, and zeaxhantin in eye health and disease. Antioxidants. 2020;9(11):1046. doi: 10.3390/antiox9111046.

Andreas S. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117(29-30):513-20.

Jiali W, Xiaodong S. Complement system and age related macular degeneration: Drugs and challenges. Drug Design, Development, Therapy 2019;13:2413-25.

Schimdt U, Garcia A, Gerendas B, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retinal Specialists. Ophthalmologica Guideline 2019;242:123-62.

Downloads

Published

01-12-2021

How to Cite

Alicia Pricelda. (2021). Tren Terapi Age-Related Macular Degeneration. Cermin Dunia Kedokteran, 48(12), 745–747. https://doi.org/10.55175/cdk.v48i12.176